Importance of the field: The use of the first generation non-nucleoside reverse transcriptase
inhibitor efavirenz (EFV) as a component of first-line antiretroviral therapy has been …

Introduction As highly active antiretroviral therapy (HAART) transforms human
immunodeficiency virus (HIV) into a manageable chronic disease, new challenges are …

Aims Genetic factors, notably CYP2B6 516G→ T [rs3745274] and 983T→ C [rs28399499],
explain much of the interindividual variability in efavirenz pharmacokinetics, but data from …

Background Rifampicin induces expression of the cytochrome P450 isoenzyme 2B6
(CYP2B6), which metabolizes efavirenz. The CYP2B6 516G> T polymorphism impairs …

Introduction: High levels of adherence to antiretroviral therapy (ART) are central to HIV
management. The objective of this study was to compare multiple measures of adherence …

Objectives: An efavirenz-based antiretroviral therapy (ART) regimen is preferred for children
more than 3 years of age with tuberculosis. However, rifampin, a key component of …

Setting: Rifampicin may reduce plasma efavirenz concentrations by inducing the expression
of the cytochrome P450 2B6, which metabolizes efavirenz. However, there is no data in …

Background Our main objectives were to study the population pharmacokinetics of efavirenz
and to explore the adequacy of dosing guidelines. Methods A total of 33 HIV-1-infected …

Background: Malnutrition may impact the pharmacokinetics (PKs) of antiretroviral
medications and virologic responses in HIV-infected children. The authors therefore …

Objectives To obtain data on the pharmacokinetics of efavirenz in children in clinical
practice. Methods HIV-1-infected children received efavirenz capsules or tablets in …